Fig. 1From: Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trialFlowchart of enrolled patients. MIDAS: MIgraine Disability ASsessment. T6, T9, T12: follow-up visits at six, nine, and twelve months after first erenumab administrationBack to article page